Xtant Medical Receives FDA 510(k) Clearance for InTice -C Porous Titanium Cervical Interbody System BELGRADE, MT.

Xtant Medical Receives FDA

510(k) Clearance for InTice -C Porous Titanium Cervical Interbody System

BELGRADE, MT., May. 21, 2018 -- Xtant

Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices,

announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice -C

Porous Titanium Cervical Interbody System.

InTice-C is designed using OsteoSync Ti,

a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely

resembles the bioscaffold of cancellous bone, and further combines Xtant Medical's hardware and biologic portfolios. In addition

to InTice-C serving as a bioactive scaffold, it is also cleared for use with Xtant's proprietary allograft lines, including

OsteoSponge , 3Demin Cortical Fibers, and OsteoVive viable cell allograft.

"InTice-C represents Xtant's latest addition to our

spinal implant portfolio and is our first spinal implant to be engineered using a best-in-class porous titanium material"

stated Dr. Gregory Juda, Chief Scientific Officer and General Manager of Xtant Medical. "The porous architecture of the titanium

was designed to improve implant fixation, both prior and post fusion. We expect a positive reception of this technology from our

surgeon customers in the cervical spine market."

The InTice-C Is designed to provide cervical intervertebral

body fusion options for each patient's varied anatomy. It is offered in multiple footprint, height and endplate options.

The commercial pure titanium structure offers continuous pore interconnectivity from the top to the bottom as well as from the

outer perimeter to the large central graft cavity of the implant. This optimizes vascularization to the fusion site allowing the

implant to be a participant in the fusion process. The implant utilizes machined endplate structures in conjunction with the inherent

texture of the porous titanium to provide migration resistance. The implant is offered in individual sterile packages. InTice-C

was developed in collaboration with Sites Medical.

InTice-C will help the Company further penetrate the $285 million

dollar cervical spine market. Xtant's other cervical interbody options include Calix -C, Calix-C PC, Atrix-C ,

and Irix -C, which offer PEEK, PEEK with a plasma-coated titanium, a structural biologic solution, and a standalone

cervical option, respectively.

Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international

markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics

for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment

of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies

in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete

in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include

statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such

as ''continue,'' ''efforts,'' ''expects,'' ''anticipates,'' ''intends,'' ''plans,'' ''believes,'' ''estimates,'' ''projects,''

''forecasts,'' ''strategy,'' ''will,'' ''goal,'' ''target,'' ''prospects,'' ''potential,'' ''optimistic,'' ''confident,'' ''likely,''

''probable'' or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking

statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially

depending on a variety of important factors, including, among others: the ability to increase revenue; the ability to achieve

expected results; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and

retain qualified technical personnel and members of the Company's management team; influence by Company management; the security

of our technology systems; government and third-party coverage and reimbursement for Company products; the ability to obtain donors

to support the biologic portfolio; the availability of Company facilities; the ability to remain accredited with the American

Association of Tissue Banks; the ability to obtain regulatory approvals; government regulations; product liability claims and

other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability

to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property;

the ability to use net operating loss carry-forwards to offset future taxable income; the ability to service Company debt; the

ability to comply with covenants in the Company's senior credit facility; the ability to raise additional financing and other

factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 filed

with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without

limitation its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. Investors are encouraged to read the Company's

filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Investors should

not place considerable reliance on the forward-looking statements contained in this release. The Company undertakes no obligation

to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or

to reflect the occurrence of unanticipated events, except as required by law. The Company's business is subject to substantial

risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration

to these risks and uncertainties. All forward-looking statements attributable to us or persons acting on our behalf

are expressly qualified in their entirety by this cautionary statement.

Xtant Medical Holdings, Inc.